SEC 13F Intelligence

Managers / Q2 2021 · view latest →

Burrage Capital Management LLC

CIK 0001796461 · 314 COMMONWEALTH AVENUE, #4, BOSTON, MA, 02115 · 617-410-4770

Reported Value
$100M
Q2 2021
Positions
22
Filings on Record
8
2020–present window
Filed
Aug 16, 2021
original filing

Summary

Burrage Capital Management LLC reported $100M in U.S.-listed holdings across 22 positions for Q2 2021.

Its largest position, BCRX, represents 13.7% of the portfolio.

Compared with Q1 2021, the fund opened 3 new positions and exited 8.

Portfolio Metrics

Turnover
+21.5%
vs prior filed quarter
Top-10 Concentration
+70.7%
share of reported value
Largest Position
+13.7%
Biocryst Pharmaceuticals
New / Exited
3 / 8
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $149MQ4 ’19Q1 ’20: $102MQ1 ’20Q2 ’20: $143MQ2 ’20Q3 ’20: $127MQ3 ’20Q4 ’20: $131MQ4 ’20Q1 ’21: $123MQ1 ’21Q2 ’21: $100MQ2 ’21Q3 ’21: $0Q3 ’21filingsflow.com

Portfolio Composition

By security type
Common Stock: 84.8%Other: 15.2%
  • Common Stock · 84.8% · $85M
  • Other · 15.2% · $15M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AMICUS THERAPEUTICS INCNEW+500.0K500.0K+$5M$5M
VERASTEM INCNEW+705.6K705.6K+$3M$3M
RVMDREVOLUTION MEDICINES INCNEW+50.0K50.0K+$2M$2M
PLXPROTALIX BIOTHERAPEUTICS INCSOLD OUT−2.13M0−$9M$0
PTCTPTC THERAPEUTICS INCSOLD OUT−160.4K0−$8M$0
CARA THERAPEUTICS INCSOLD OUT−180.0K0−$4M$0
FULCFULCRUM THERAPEUTICS INCSOLD OUT−319.8K0−$4M$0
TRICIDA INCSOLD OUT−658.9K0−$3M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

22 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BCRXBIOCRYST PHARMACEUTICALS INChistory →COM13.71%$14M864.9K
2NTLAINTELLIA THERAPEUTICS INChistory →COM10.33%$10M63.6K
3EPIZYME INCCOM6.97%$7M836.8K
4ESSA PHARMA INCCOM NEW6.80%$7M237.4K
5NEONEOGENOMICS INChistory →COM6.70%$7M147.9K
6MEI PHARMA INCCOM6.66%$7M2.33M
7CRNXCRINETICS PHARMACEUTICALS INhistory →COM5.57%$6M294.6K
8CYTKCYTOKINETICS INChistory →COM4.85%$5M244.7K
9AMICUS THERAPEUTICS INCCOM4.83%$5M500.0K
10HRMYHARMONY BIOSCIENCES HLDGS INhistory →COM4.25%$4M150.0K
11INOZYME PHARMA INCCOM4.14%$4M242.5K
12Y-MABS THERAPEUTICS INCCOM3.88%$4M114.5K
13MIRMMIRUM PHARMACEUTICALS INChistory →COM3.57%$4M205.9K
14ADC THERAPEUTICS SASHS3.05%$3M124.9K
15VERASTEM INCCOM2.88%$3M705.6K
16MERUS N VCOM2.76%$3M130.7K
17GERNGERON CORPhistory →COM2.70%$3M1.91M
18AVROBIO INCCOM2.18%$2M244.9K
19RVMDREVOLUTION MEDICINES INChistory →COM1.59%$2M50.0K
20BDTXBLACK DIAMOND THERAPEUTICS Ihistory →COM1.35%$1M110.4K
21G1 THERAPEUTICS INCCOM1.05%$1M47.7K
22TURNING POINT THERAPEUTICS ICOM0.17%$169,0002.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2021$01Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$100M22Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$123M27May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$131M25Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$127M27Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$143M26Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$102M31May 14, 202013F-HRchanges · EDGAR ↗
Q4 2019$149M29Feb 14, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.